Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan

被引:32
|
作者
Gaglio, Paul [1 ,2 ]
Marfo, Kwaku [1 ,2 ]
Chiodo, Joseph, III [3 ]
机构
[1] Montefiore Med Ctr, Div Hepatol, Bronx, NY 10467 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Otsuka Amer Pharmaceut Inc, Med Sci Liaison, Rockville, MD USA
关键词
Arginine vasopressin; MELD score; Portal hypertension; Vasopressin receptor antagonists; SERUM SODIUM CONCENTRATION; V-2 RECEPTOR ANTAGONIST; PRETRANSPLANT HYPONATREMIA; HEPATIC-ENCEPHALOPATHY; RISK-FACTORS; ASCITES; MULTICENTER; SATAVAPTAN; CONIVAPTAN; MANAGEMENT;
D O I
10.1007/s10620-012-2276-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hyponatremia is common in patients with cirrhosis and portal hypertension, and is characterized by excessive renal retention of water relative to sodium due to reduced solute-free water clearance. The primary cause is increased release of arginine vasopressin. Hyponatremia is associated with increased mortality in cirrhotic patients, those with end-stage liver disease (ESLD) on transplant waiting lists, and, in some studies, posttransplantation patients. Clinical evidence suggests that adding serum sodium to model for ESLD (MELD) scoring identifies patients in greatest need of liver transplantation by improving waiting list mortality prediction. Hyponatremia is also associated with numerous complications in liver disease patients, including severe ascites, hepatic encephalopathy, infectious complications, renal impairment, increased severity of liver disease in cirrhosis, and increased hospital stay and neurologic/infectious complications posttransplant. Vasopressin receptor antagonists, which act to increase free water excretion (aquaresis) and thereby increase serum sodium concentration, have been evaluated in patients with hypervolemic hyponatremia (including cirrhosis and heart failure) and euvolemic hyponatremia (SIADH). Tolvaptan, a selective vasopressin V-2-receptor antagonist, is the only oral agent in this class approved for raising sodium levels in hypervolemic and euvolemic hyponatremia. The SALT trials showed that tolvaptan treatment rapidly and effectively resolved hyponatremia in these settings, including cirrhosis, and it has been shown that this agent can be safely and effectively used in long-term treatment. Fluid restriction should be avoided during the first 24 h of treatment to prevent overly rapid correction of hyponatremia, and tolvaptan should not be used in patients who cannot sense/respond to thirst, anuric patients, hypovolemic patients, and/or those requiring urgent intervention to raise serum sodium acutely.
引用
收藏
页码:2774 / 2785
页数:12
相关论文
共 50 条
  • [21] Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema
    Hiramine, Yasunari
    Uto, Hirofumi
    Imamura, Yasushi
    Hiwaki, Takuya
    Kure, Takeshi
    Ijuin, Sho
    Oda, Kohei
    Mawatari, Seiichi
    Kumagai, Kotaro
    Tokunaga, Koki
    Higashi, Hirofumi
    Kanetsuki, Ichiro
    Kubozono, Osamu
    Maenohara, Shigeho
    Ido, Akio
    HEPATOLOGY RESEARCH, 2017, 47 (06) : 542 - 557
  • [22] LIXIVAPTAN Vasopressin V2 Receptor Antagonist Treatment of Heart Failure Treatment of Hyponatremia
    Daifallah, S.
    Zmily, H. D.
    Alqwasmi, A. H.
    Zayed, H.
    Ghali, J. K.
    DRUGS OF THE FUTURE, 2011, 36 (05) : 359 - 370
  • [23] INFLUENCE OF VASOPRESSIN V2-RECEPTOR ANTAGONIST ON CNS-INDUCED NATRIURESIS
    LEE, SL
    HOGLUND, AU
    SJOQUIST, M
    ACTA PHYSIOLOGICA SCANDINAVICA, 1991, 143 (01): : A38 - A38
  • [24] Double-Blind, Placebo-Controlled, Multicenter Trial of a Vasopressin V2-Receptor Antagonist in Patients with Schizophrenia and Hyponatremia
    Josiassen, Richard C.
    Goldman, Morris
    Jessani, Meera
    Shaughnessy, Rita A.
    Albazzaz, Ala
    Lee, Jennifer
    Ouyang, John
    Orlandi, Cesare
    Czerwiec, Frank
    BIOLOGICAL PSYCHIATRY, 2008, 64 (12) : 1097 - 1100
  • [25] Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure
    Veeraveedu, Punniyakoti T.
    Watanabe, Kenichi
    Ma, Meilei
    Palaniyandi, Suresh S.
    Yamaguchi, Ken'ichi
    Kodama, Makoto
    Aizawa, Yoshifusa
    BIOCHEMICAL PHARMACOLOGY, 2008, 75 (06) : 1322 - 1330
  • [26] Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?
    Greenberg, Arthur
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (06) : 904 - 907
  • [27] Effect of vasopressin V2-receptor antagonist tolvaptan on syndrome of inappropriate antidiuresis (SIAD) after transsphenoidal pituitary surgery: recovery of measured osmolality
    Tosaka, Masahiko
    Yamaguchi, Rei
    Itabashi, Yutaro
    Mukada, Naoto
    Tsuneoka, Haruka
    Takahashi, Kentaro
    Nakamura, Shunsuke
    Nakazawa, Takahiko
    Yoshimoto, Yuhei
    HELIYON, 2022, 8 (10)
  • [28] Vasopressin Deficiency and Vasodilatory State in End-Stage Liver Disease
    Wagener, Gebhard
    Kovalevskaya, Galina
    Minhaz, Moury
    Mattis, Fallon
    Emond, Jean C.
    Landry, Donald W.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2011, 25 (04) : 665 - 670
  • [29] Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia
    Miyazaki, T
    Yamamura, Y
    Onogawa, T
    Nakamura, S
    Kinoshita, S
    Nakayama, S
    Fujiki, H
    Mori, T
    ENDOCRINOLOGY, 2005, 146 (07) : 3037 - 3043
  • [30] The vasopressin V2-receptor antagonist, tolvaptan, can not only induce aquaresis but also enhance natriuresis in heart failure patients refractory to loop diuretics
    Ikeda, Y.
    Inomata, T.
    Iida, Y.
    Nabeta, T.
    Iwamoto, M.
    Ishii, S.
    Sato, T.
    Naruke, T.
    Koitabashi, T.
    Niwano, S.
    EUROPEAN HEART JOURNAL, 2013, 34 : 624 - 624